株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非黒色腫皮膚がん治療の世界市場

Global Non-melanoma Skin Cancer Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 305015
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
非黒色腫皮膚がん治療の世界市場 Global Non-melanoma Skin Cancer Market 2014-2018
出版日: 2014年05月23日 ページ情報: 英文 119 Pages
概要

非黒色腫皮膚がんは世界中で最も一般的に見られる癌の一種です。非黒色腫皮膚がんには2種類あります。ひとつはBCCで基底細胞に発生し、もうひとつはSCCでこちらは顔や耳、首、唇および手の甲などに発症します。非黒色腫皮膚がんは、紫外線を過剰に浴びることが原因となって発症します。治療法としては外科手術、レーザー療法、冷却療法、クリーム、放射線療法、化学療法、また光線力学療法(PDT)があります。非黒色腫皮膚がん治療の世界市場は2013年から2018年までの期間、27.93%の年平均成長率(CAGR)で拡大を続けると予測されます。

当レポートは非黒色腫皮膚がん治療の世界市場を取り上げ、業界の多くの専門家からのデータ、情報をもとに詳細な市場分析を行っています。当レポートでは以下の各市場分野それぞれの収益額から市場規模を導出しています。

第1章 エグゼクティブ・サマリー

第2章 略語表

第3章 当レポートのカバー範囲

  • 市場概要
  • 提供内容

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 序論

第6章 市場状況

  • 市場概要
  • 市場規模および将来予測
  • 非黒色腫皮膚がん治療薬の世界市場
    • 市場規模および将来予測
  • 日光角化症治療薬の世界市場
    • 市場概要
    • 市場規模および将来予測
  • BCC、SCC、および日光角化症治療薬のトップセラー
  • ファイブフォース分析

第7章 タイプ別市場分析

  • タイプ別非黒色腫皮膚がん治療薬世界市場
    • BCC
    • SCC
  • BCC治療薬世界市場
    • 市場規模および将来予測
  • SCC治療薬世界市場
    • 市場規模および将来予測

第8章 パイプライン分析

第9章 地域市場分析

  • 非黒色腫皮膚がん治療薬世界市場の地域別分類

第10章 購入基準

第11章 市場成長促進要因

第12章 市場成長促進要因とそれによる影響

第13章 市場の課題

第14章 市場成長促進要因と市場の課題とがもたらす影響

第15章 市場動向

第16章 市場動向とそれによる影響

第17章 ベンダー状況

  • 市場シェア分析
  • 日光角化症治療薬世界市場
  • その他の重要ベンダー

第18章 無侵襲治療市場

  • 非黒色腫皮膚がんの放射線療法世界市場
    • 市場規模および将来予測
  • 非黒色腫皮膚がんの冷却療法世界市場
    • 市場規模および将来予測
  • 非黒色腫皮膚がんの光線力学療法(PDT)世界市場
    • 市場規模および将来予測
  • 非黒色腫皮膚がんのレーザー療法世界市場
    • 市場規模および将来予測
  • ベンダーシェア
    • 非黒色腫皮膚がんの放射線療法機器世界市場
    • 非黒色腫皮膚がんの冷却療法機器世界市場
    • 非黒色腫皮膚がんの光線力学療法(PDT)機器世界市場
    • 非黒色腫皮膚がんのレーザー療法機器世界市場

第19章 主要ベンダー分析

  • Elekta AB
  • F. Hoffmann-La Roche Ltd.
  • iCAD Inc.
  • Meda AB
  • Valeant Pharmaceuticals International Inc.
  • Varian Medical Systems Inc.

第20章 関連レポート

目次
Product Code: IRTNTR3605

About Non-melanoma Skin Cancer

Non-melanoma skin cancer is one of the most common types of cancer in the world. It develops in the upper layers of the skin, but not in melanocytes. There are two types of non-melanoma skin cancer: BCC, which starts in the basal cells, and SCC, which starts in the squamous cells. BCC usually develops in the areas such as the head and neck, whereas SCC starts in the face, ears, neck, lips, and backs of the hands. These can also grow in wounds or chronic skin sores. Non-melanoma skin cancer is caused by unprotected and excessive exposure to UV radiation. It affects men more than women. It can be cured effectively if it is detected early. Treatment for non-melanoma skin cancer includes surgery, laser therapy, cryotherapy, creams, radiotherapy, chemotherapy, and PDT.

TechNavio's analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments:

Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis

Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy

TechNavio's report, the Global Non-melanoma Skin Cancer Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and, the EMEA and the APAC region; and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Elekta AB
  • F. Hoffmann-la Roche Ltd.
  • iCAD Inc.
  • Meda AB
  • Valeant Pharmaceuticals Inc.
  • Varian Medical Systems Inc.

Other Prominent Vendors

  • Aqua Pharmaceuticals LLC
  • Almirall SA
  • Biofrontera AG
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Co.
  • Cannabis Science Inc.
  • Cellceutix Corp.
  • Eli Lilly and Co.
  • Galderma SA
  • GENEXTRA SpA
  • IRX Therapeutics Inc.
  • LEO Pharma A/S
  • Merck & Co. Inc.
  • Moberg Pharma AB
  • Mylan Pharmaceutical Inc.
  • Novartis International AG
  • Oncothyreon Inc.
  • Sun Pharma Industries Ltd.

Market Driver

  • Increasing Incidence of Non-melanoma Skin Cancer

For a full, detailed list, view our report.

Market Challenge

  • Availability of Alternative Treatments

For a full, detailed list, view our report.

Market Trend

  • Emergence of Combination Therapies

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Global Non-melanoma Skin Cancer Drugs Market
    • 06.3.1. Market Size and Forecast
  • 06.4. Global Actinic Keratosis Drugs Market
    • 06.4.1. Market Overview
    • 06.4.2. Market Size and Forecast
  • 06.5. Top Selling Drugs for the Treatment of BCC, SCC, and Actinic Keratosis
  • 06.6. Five Forces Analysis

07. Market Segmentation by Type

  • 07.1. Global Non-melanoma Skin Cancer Drugs Market by Type
    • 07.1.1. BCC
    • 07.1.2. SCC
  • 07.2. Global BCC Drugs Market
    • 07.2.1. Market Size and Forecast
  • 07.3. Global SCC Drugs Market
    • 07.3.1. Market Size and Forecast

08. Pipeline Analysis

09. Geographical Segmentation

  • 09.1. Global Non-melanoma Skin Cancer Market by Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Market Share Analysis 2013
  • 17.2. Global Actinic Keratosis Drugs Market
  • 17.3. Other Prominent Vendors

18. Non-invasive Treatment Market

  • 18.1. Global Non-melanoma Skin Cancer Radiotherapy Market
    • 18.1.1. Market Size and Forecast
  • 18.2. Global Non-melanoma Skin Cancer Cryotherapy Market
    • 18.2.1. Market Size and Forecast
  • 18.3. Global Non-melanoma Skin Cancer PDT Market
    • 18.3.1. Market Size and Forecast
  • 18.4. Global Non-melanoma Skin Cancer Laser Therapy Market
    • 18.4.1. Market Size and Forecast
  • 18.5. Vendor Share
    • 18.5.1. Global Non-melanoma Skin Cancer Radiotherapy Equipment Market
    • 18.5.2. Global Non-melanoma Skin Cancer Cryotherapy Equipment Market
    • 18.5.3. Global Non-melanoma Skin Cancer PDT Equipment Market
    • 18.5.4. Global Non-melanoma Skin Cancer Laser Equipment Market

19. Key Vendor Analysis

  • 19.1. Elekta AB
    • 19.1.1. Key Facts
    • 19.1.2. Business Description
    • 19.1.3. Product Categorization
    • 19.1.4. Revenue by Product Offerings
    • 19.1.5. Revenue Comparison by Geographical Segmentation 2012 and 2013
    • 19.1.6. Revenue Comparison by Geographical Segmentation
    • 19.1.7. Business Strategy
    • 19.1.8. Key Developments
    • 19.1.9. SWOT Analysis
    • 19.1.10. Strengths
    • 19.1.11. Weaknesses
    • 19.1.12. Opportunities
    • 19.1.13. Threats
  • 19.2. F. Hoffmann-La Roche Ltd.
    • 19.2.1. Key Facts
    • 19.2.2. Business Description
    • 19.2.3. Business Segmentation
    • 19.2.4. Revenue by Business Segmentation
    • 19.2.5. Geographical Sales Segmentation by Business Segments
    • 19.2.6. Business Strategy
    • 19.2.7. Key Information
    • 19.2.8. SWOT Analysis
    • 19.2.9. Strengths
    • 19.2.10. Weaknesses
    • 19.2.11. Opportunities
    • 19.2.12. Threats
  • 19.3. iCAD Inc.
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison by Business Segmentation 2012 and 2013
    • 19.3.6. Revenue by Geographical Segmentation
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
    • 19.3.9. SWOT Analysis
    • 19.3.10. Strengths
    • 19.3.11. Weaknesses
    • 19.3.12. Opportunities
    • 19.3.13. Threats
  • 19.4. Meda AB
    • 19.4.1. Key Facts
    • 19.4.2. Business Description
    • 19.4.3. Product Segmentation
    • 19.4.4. Revenue by Product Segmentation
    • 19.4.5. Revenue Comparison by Product Segmentation 2012 and 2013
    • 19.4.6. Revenue by Geographical Segmentation
    • 19.4.7. Business Strategy
    • 19.4.8. Key Developments
    • 19.4.9. SWOT Analysis
    • 19.4.10. Strengths
    • 19.4.11. Weaknesses
    • 19.4.12. Opportunities
    • 19.4.13. Threats
  • 19.5. Valeant Pharmaceuticals International Inc.
    • 19.5.1. Key Facts
    • 19.5.2. Business Description
    • 19.5.3. Business Segmentation
    • 19.5.4. Revenue Comparison by Business Segmentation 2011-2013
    • 19.5.5. Revenue by Geographical Segmentation
    • 19.5.6. Business Strategy
    • 19.5.7. Key Developments
    • 19.5.8. SWOT Analysis
    • 19.5.9. Strengths
    • 19.5.10. Weaknesses
    • 19.5.11. Opportunities
    • 19.5.12. Threats
  • 19.6. Varian Medical Systems Inc.
    • 19.6.1. Key Facts
    • 19.6.2. Business Description
    • 19.6.3. Business Segmentation
    • 19.6.4. Revenue by Business Segmentation
    • 19.6.5. Revenue Comparison by Business Segmentation 2013 and 2012
    • 19.6.6. Revenue by Geographical Segmentation
    • 19.6.7. Business Strategy
    • 19.6.8. Key Developments
    • 19.6.9. SWOT Analysis
    • 19.6.10. Strengths
    • 19.6.11. Weaknesses
    • 19.6.12. Opportunities
    • 19.6.13. Threats

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Non-melanoma Skin Cancer Market Segmentation by Type
  • Exhibit 3: Global Non-melanoma Skin Cancer Market 2013-2020 (US$ million)
  • Exhibit 4: Global Non-melanoma Skin Cancer Drugs Market 2013-2020 (US$ million)
  • Exhibit 5: Global Actinic Keratosis Drugs Market 2013-2020 (US$ million)
  • Exhibit 6: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type
  • Exhibit 7: Global Non-melanoma Skin Cancer Drugs Market Segmentation by Type 2013
  • Exhibit 8: Global BCC Drugs Market 2013-2020 (US$ million)
  • Exhibit 9: Global SCC Drugs Market 2013-2020 (US$ million)
  • Exhibit 10: Global Non-melanoma Skin Cancer Market by Geographical Segmentation 2013
  • Exhibit 11: Global Actinic Keratosis Drugs Market by Vendor Segmentation 2013
  • Exhibit 12: Global Non-melanoma Skin Cancer Radiotherapy Market 2013-2020 (US$ million)
  • Exhibit 13: Global Non-melanoma Skin Cancer Cryotherapy Market 2013-2020 (US$ million)
  • Exhibit 14: Global Non-melanoma Skin Cancer PDT Market 2013-2020 (US$ million)
  • Exhibit 15: Global Non-melanoma Skin Cancer Laser Therapy Market 2013-2020 (US$ million)
  • Exhibit 16: Global Non-melanoma Skin Cancer Radiotherapy Equipment Market by Vendor Segmentation 2013
  • Exhibit 17: Global Non-melanoma Skin Cancer Cryotherapy Equipment Market by Vendor Segmentation 2013
  • Exhibit 18: Global Non-melanoma Skin Cancer PDT Equipment Market by Vendor Segmentation 2013 51
  • Exhibit 19: Vendors in Global Non-melanoma Skin Cancer Laser Equipment Market
  • Exhibit 20: Elekta AB: Product Categorization
  • Exhibit 21: Elekta AB: Revenue by Product Offerings 2013
  • Exhibit 22: Elekta AB: Revenue Comparison by Geographical Segmentation 2012 and 2013 (US$ million)
  • Exhibit 23: Elekta AB: Revenue Comparison by Geographical Segmentation 2013
  • Exhibit 24: F. Hoffmann-la Roche Ltd.: Business Segmentation 2013
  • Exhibit 25: F. Hoffmann-la Roche Ltd.: Revenue by Business Segmentation 2012 and 2013
  • Exhibit 26: F. Hoffmann-la Roche Ltd.: Revenue of Pharmaceuticals Division by Geographical Segmentation 2013
  • Exhibit 27: F. Hoffmann-la Roche Ltd.: Revenue of Diagnostics Division by Geographical Segmentation 2013
  • Exhibit 28: iCAD Inc.: Business Segmentation
  • Exhibit 29: iCAD Inc.: Revenue by Business Segmentation 2013
  • Exhibit 30: iCAD Inc.: Revenue Comparison by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 31: iCAD Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 32: Meda AB: Product Segmentation
  • Exhibit 33: Meda AB: Revenue by Product Segmentation 2013
  • Exhibit 34: Meda AB: Revenue Comparison by Product Segmentation 2012 and 2013 (US$ billion)
  • Exhibit 35: Meda AB: Revenue by Geographical Segmentation 2013
  • Exhibit 36: Valeant Pharmaceuticals International Inc.: Business Segmentation 2013
  • Exhibit 37: Valeant Pharmaceuticals International Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ million)
  • Exhibit 38: Valeant Pharmaceuticals International Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 39: Varian Medical Systems Inc.: Business Segmentation
  • Exhibit 40: Varian Medical Systems Inc.: Revenue by Business Segmentation 2013
  • Exhibit 41: Varian Medical Systems Inc.: Revenue Comparison by Business Segmentation (US$ million)
  • Exhibit 42: Varian Medical Systems Inc.: Revenue Segmentation by Geographical Segmentation 2013
Back to Top